UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
June 4, 2001
- ------------------
(Date of earliest event reported)


LABORATORY CORPORATION OF AMERICA HOLDINGS
- ------------------------------------------
(Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission          (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                   Number)


358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
- -------------------------------------------------------
(Address of principal executive offices)

336-229-1127
- ------------
(Registrant's telephone number, including area code)




ITEM 5. OTHER EVENTS

   Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that it has completed the acquisition of Minneapolis-based
ViroMed Inc.  ViroMed had clinical laboratory revenues for the
twelve months ended December 31, 2000 of approximately $25.2
million and earnings before interest, taxes, depreciation and
amortization of approximately $5.1 million.  Terms of the
transaction were not disclosed.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      (20)  Press release of the Company dated June 4, 2001.



SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                        (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ----------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: June 4, 2001

Laboratory Corporation of America-Registered Trademark- Holdings
358 South Main Street
Burlington, NC 27215
Telephone:  336-584-5171


FOR IMMEDIATE RELEASE

Contact:     336-436-4855       Shareholder Direct:     800-LAB-0401
             Pamela Sherry                              www.labcorp.com


LABCORP-REGISTERED TRADEMARK-ACQUIRES VIROMED INC.


Leading Virology Testing Laboratory Expands LabCorp's Esoteric Presence
in the Midwest


Burlington, NC, June 4, 2001 - Laboratory Corporation of America-
Registered Trademark-Holdings (LabCorp-Registered Trademark-) (NYSE:
LH) today announced that it has completed the acquisition of
Minneapolis-based ViroMed Inc.  ViroMed had clinical laboratory
revenues for the twelve months ended December 31, 2000 of approximately
$25.2 million and earnings before interest, taxes, depreciation and
amortization of approximately $5.1 million.  Terms of the transaction
were not disclosed.

Established in 1982, ViroMed is a national leader in specialized
clinical diagnostic testing in virology, molecular biology, serology,
microbiology, mycology and mycobacteriology, as well as in tissue/eye
bank testing.  ViroMed is also a leader in antiviral clinical trials
testing and is one of the foremost suppliers of cell culture products
in North America.

"We are delighted to add this premier virology testing laboratory to
our industry-leading molecular diagnostic services," said Thomas P. Mac
Mahon, chairman and chief executive officer of LabCorp.  "ViroMed has
helped set the standard for high-end virologic infectious disease
testing and is the centerpiece in our plan to establish a Center of
Excellence for esoteric testing in Minneapolis.  By combining the
technical leadership of ViroMed with LabCorp's national logistics
network, we further strengthen our leadership position in infectious
disease testing.  In addition, ViroMed's specialized laboratory space
provides us significant, additional esoteric testing capacity and the
flexibility to more efficiently direct workflow throughout the Company."

The first clinical laboratory to fully embrace genomic testing,
Laboratory Corporation of America-Registered Trademark-Holdings
(LabCorp-Registered Trademark-) has been a pioneer in commercializing
new diagnostic technologies.  As a national laboratory with annual
revenues of $1.9 billion in 2000 and over 18,000 employees, the Company
offers more than 4,000 clinical tests ranging from simple blood
analyses to sophisticated molecular diagnostics. Serving over 200,000
clients nationwide, LabCorp leverages its expertise in innovative
clinical testing technology with its Centers of Excellence. The Center
for Molecular Biology and Pathology, in Research Triangle Park
(RTP), North Carolina, develops applications for polymerase chain
reaction (PCR) technology. LabCorp's National Genetics Institute in Los
Angeles is an industry leader in developing novel, highly sensitive PCR
methods for testing hepatitis C and other infectious agents, and its
Center for Esoteric Testing in Burlington, North Carolina, performs the
largest volume of specialty testing in the network.  LabCorp's clients
include physicians, state and federal government, managed care
organizations, hospitals, clinics, pharmaceutical and Fortune 1000
companies, and other clinical laboratories.

The Company noted that each of the above forward-looking statements is
subject to change based on various important factors, including without
limitation, competitive actions in the marketplace and adverse actions
of governmental and other third-party payors.  Further information on
potential factors that could affect the Company's financial results is
included in the Company's Form 10-K for the year ended December 31,
2000 and subsequent SEC filings.